Rani Therapeutics Holdings (RANI) Amortization of Deferred Charges (2022 - 2025)

Rani Therapeutics Holdings' Amortization of Deferred Charges history spans 4 years, with the latest figure at $33000.0 for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 43.1% to $33000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was $149000.0, a 35.78% decrease, with the full-year FY2025 number at $207000.0, down 10.78% from a year prior.
  • Amortization of Deferred Charges came in at $33000.0 for Q4 2025, down from $58000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $58000.0 in Q4 2022, with the low at $19000.0 in Q3 2022.
  • Historically, Amortization of Deferred Charges has averaged $53428.6 across 4 years, with a median of $58000.0 in 2022.
  • Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 205.26% in 2023 and later tumbled 43.1% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $58000.0 in 2022, then changed by 0.0% to $58000.0 in 2023, then changed by 0.0% to $58000.0 in 2024, then plummeted by 43.1% to $33000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for RANI at $33000.0 in Q4 2025, $58000.0 in Q3 2025, and $58000.0 in Q2 2025.